GlycoMimetics Days Sales in Receivables 2012-2025 | CBIO
GlycoMimetics days sales in receivables from 2012 to 2025. Days sales in receivables can be defined as the average number of days it takes to collect outstanding receiveable amounts from customers.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.010B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
